Press release from Companies
Publicerat: 2025-07-25 14:18:45
Redsense Medical has received a preemptive order from a US distribution partner as a proactive measure in anticipation of a pending potential tariff increase.
The order, originally scheduled for fulfillment in September, represents an estimated quarters worth of product with that distribution partner, and has been advanced to July as part of a strategic effort to mitigate potential cost impacts associated with upcoming trade changes. The company continues to monitor trade developments closely and remains committed to supporting its partners through flexible and responsive supply chain planning.
"This move demonstrates the strength of our partnerships and our ability to adapt quickly to market shifts. Together with other orders early in July this also already secures year on year growth early into the third quarter." says Sebastien Bollue, CEO of Redsense Medical AB.
Moreover the Clamp launch is on track with primary instruction translations made and first sample orders to distribution partners received. Distribution partners have started clinical demonstrations and discussions with providers, where the company has started a direct approach in Germany.
Contact information
For more information, please contact:
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS).